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Abstract
Purpose: This study determined the effects of 28 days of heavy resistance exercise combined with the
nutritional supplement, NO-Shotgun®, on body composition, muscle strength and mass, markers of
satellite cell activation, and clinical safety markers.
Methods: Eighteen non-resistance-trained males participated in a resistance training program (3 × 10-
RM) 4 times/wk for 28 days while also ingesting 27 g/day of placebo (PL) or NO-Shotgun® (NO) 30 min
prior to exercise. Data were analyzed with separate 2 × 2 ANOVA and t-tests (p < 0.05).
Results: Total body mass was increased in both groups (p = 0.001), but without any significant increases
in total body water (p = 0.77). No significant changes occurred with fat mass (p = 0.62); however fat-free
mass did increase with training (p = 0.001), and NO was significantly greater than PL (p = 0.001). Bench
press strength for NO was significantly greater than PL (p = 0.003). Myofibrillar protein increased with
training (p = 0.001), with NO being significantly greater than PL (p = 0.019). Serum IGF-1 (p = 0.046) and
HGF (p = 0.06) were significantly increased with training and for NO HGF was greater than PL (p = 0.002).
Muscle phosphorylated c-met was increased with training for both groups (p = 0.019). Total DNA was
increased in both groups (p = 0.006), while NO was significantly greater than PL (p = 0.038). For DNA/
protein, PL was decreased and NO was not changed (p = 0.014). All of the myogenic regulatory factors
were increased with training; however, NO was shown to be significantly greater than PL for Myo-D (p =
0.008) and MRF-4 (p = 0.022). No significant differences were located for any of the whole blood and
serum clinical chemistry markers (p > 0.05).
Conclusion: When combined with heavy resistance training for 28 days, NO-Shotgun® is not associated
with any negative side effects, nor does it abnormally impact any of the clinical chemistry markers. Rather,
NO-Shotgun® effectively increases muscle strength and mass, myofibrillar protein content, and increases
the content of markers indicative of satellite cell activation.
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Introduction
Heavy resistance training in humans enhances muscle
protein synthesis [1-3] with concomitant increases in
muscle strength and hypertrophy [4-6]. Increases in mus-
cle protein synthesis occurring in response to resistance
training can be attributed to pre-translational (increase in
mRNA abundance) mechanisms [7], as muscle-specific
gene expression is up-regulated in order to provide an
ample supply of mRNA template to meet translational
(increases in protein synthesis/unit of mRNA) demands.
This process is critical since skeletal myocytes are multi-
nucleated and each myonucleus controls both mRNA and
protein synthesis over a finite sarcoplasmic volume (aka.
the myonuclear domain) [8].
Muscle hypertrophy is also regulated by myogenic mech-
anisms, and in response to resistance training, skeletal
muscle hypertrophy can occur through satellite cell activa-
tion. During this process, mechanical overload activates
satellite cells, which are located between the sarcolemma
and basal lamina [9]. These cells then differentiate and
proliferate, thereby donating their nuclei to pre-existing
myocytes in order to maintain the myonuclear domain
[10]. Research in humans indicates that resistance training
can increase the number of satellite cells and increase
myonuclei in the myofibril [11,12]. As such, resistance
training can increase the proportion of satellite cells and
the number of myonuclei [12], which suggests that satel-
lite cell activation is an important adaptive mechanism
involved in hypertrophy. The activation of satellite cells
[13] which accompanies resistance training can be stimu-
lated byvarious signals, including anabolic hormones
such as insulin-likegrowth factor I (IGF-I) and hepatocyte
growth factor (HGF), regulatory proteins such as the myo-
genic regulatory factors (MRFs), and nitric oxide. IGF-1 is
released from the liver and binds with membrane-bound
receptors on the sarcolemma, thereby activating intracel-
lular signaling through the Akt/mTOR pathway. IGF-I has
been shown to play a role in myogenesis by stimulating
satellite cell proliferation and differentiation [14]. HGF is
a heparin-binding growth factor that is localized in the
extracellular domain of un-stimulated skeletal muscle fib-
ers, and after stimulation by mechanical overload HGF
quickly associates with satellite cells [15]. Furthermore,
quiescent and activated satellite cells have been shown to
express the c-met receptor, which mediates the intracellu-
lar signaling response of HGF. In response to muscle
injury, HGF associates with satellite cells and co-localizes
with the c-met receptor [15]. Therefore, as HGF becomes
available for interaction with the c-met receptor, it up-reg-
ulates satellite cell activation.
The MRFs (Myo-D, myogenin, MRF-4, myf5) are a family
of muscle-specific transcription factors that play a role in
muscle hypertrophy by binding to E-boxes in the pro-
moter region of various sarcomeric genes such as myosin
heavy chain, myosin light chain, tropomyosin, troponin-
C, and creatine kinase [4] resulting in transactivation of
transcription. Furthermore, the MRFs appear to play a role
in myogenic activation by inducing myoblast differentia-
tion, as MyoD and Myf5 are believed to be involved in sat-
ellite proliferation, and myogenin and MRF-4 are
involved in satellite cell differentiation [16]. In contrast to
myf5 and Myo-D, myogenin and MRF-4 apparently regu-
late genes specific to contractile protein [17,18], including
genes involved in fast and slow fiber differentiation [19],
as myogenin has been found to accumulate in Type I fib-
ers and Myo-D in Type II fibers [20]. Human studies indi-
cate that resistance training increases MyoD, myogenin,
and MRF-4 mRNA after acute exercise bouts, and that the
expression of MyoD and myogenin are correlated with
increases in myofibrillar protein [21]. A study involving
16 wk of resistance training resulted in increased MyoD,
myogenin, MRF-4, and myf5 mRNA that were correlated
with increased myofiber size [22].
Muscle injury has been shown to increase nitric oxide syn-
thesis which mediates muscle hypertrophy associated
with satellite cell activation. Shear forces generated by
muscle contraction or retraction of damaged fibers within
the basal lamina are thought to stimulate nitric oxide syn-
thase to synthesize nitric oxide, which has been suggested
to provide the initial signal for satellite cell activation
[15]. As such, this has established a supposed link
between mechanical changes in muscle, nitric oxide syn-
thesis, and satellite cell activation.
In addition to improvements in resistance training-related
adaptations such as body composition and muscle
strength and power, various forms of nutritional supple-
mentation [i.e., creatine, protein, branched-chain amino
acids (BCAA), leucine, arginine] are thought to function
as either transcriptional co-regulators or as myogenic co-
factors, as they have been shown to differentially augment
muscle hypertrophy through increases in protein synthe-
sis and/or satellite cell activation. Whey protein and leu-
cine ingested in conjunction with eight wk of resistance
training was shown to increase muscle strength beyond
that achieved with resistance training and a carbohydrate
placebo [23]. Creatine supplemented during 12 wk of
heavy resistance training has been shown to augment
changes indicative of skeletal muscle hypertrophy, as cre-
atine resulted in increases in MHC Type I, IIa, and IIx pro-
tein, respectively, as well as a 58% increase in myofibrillar
protein content [24]. Furthermore, creatine was found to
significantly increase the expression of myogenin and
MRF-4 protein [25]. In a similar study, MRF-4 protein
expression was increased after 10 wk of resistance training
and creatine supplementation, with the increase in MRF-
4 expression being significantly correlated with anJournal of the International Society of Sports Nutrition 2009, 6:16 http://www.jissn.com/content/6/1/16
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increased mean fiber area [26]. After 16 wk of heavy resist-
ance training, creatine supplementation increased satellite
cell activation, myonuclear number, mean fiber area, and
muscle strength compared to whey protein supplementa-
tion and control [27].
Creatine supplementation has been shown to enhance
myogenic differentiation by activating the p38 MAPK
pathway, which is an intracellular signaling pathway
responsible for up-regulating skeletal muscle gene expres-
sion in response to muscle contraction. Creatine has also
been shown to increase the activity of the Akt/mTOR
pathway [28]. The Akt/mTOR pathway is an intracellular
pathway involved in increasing muscle protein synthesis.
Furthermore, the Akt/mTOR pathway can also be acti-
vated by leucine [29]. Consequently, leucine supplemen-
tation increased the levels of α-ketoisocaproate (KIC)
[30]. KIC blunts the activity of the branched-chain keto-
acid dehydrogenase (BCKDH) enzyme complex, which
decreases skeletal muscle BCAA oxidation that has been
shown to occur during exercise [31]. This is further sup-
ported by the fact BCAA have been shown to effectively
suppress exercise-induced skeletal muscle proteolysis
[32].
Along with the typical resistance training adaptations such
as improvements in body composition, and increases in
muscle strength and myofibrillar protein content, based
on the aforementioned data a nutritional supplement
containing creatine, leucine, KIC, and arginine ingested in
conjunction with heavy resistance training could conceiv-
ably increase muscle hypertrophy through mechanisms
associated with increased muscle protein synthesis,
decreased muscle proteolysis, and/or satellite cell activa-
tion. However, there is a paucity of data demonstrating
the effectiveness of such a nutritional product on muscle
strength and mass and satellite cell activation. Therefore,
the purpose of this study was to determine the effects of
28 days of heavy resistance exercise combined with con-
suming a commercially available pre-workout supple-
ment, NO-Shotgun®, on body composition, muscle
strength and mass, myofibrillar protein content, markers
of satellite cell activation, and clinical safety markers in
males. Based on previous research with individual com-
pounds contained in NO-Shotgun®  [15,25-27], we
hypothesized that 28 days of heavy resistance training
combined with this supplement would preferentially
increase muscle strength and mass and stimulate the
expression of markers indicative of satellite cell activation,
without having any adverse effects on blood clinical
chemistry markers.
Methods
Participants
Eighteen apparently healthy, recreationally active, non-
resistance trained [no consistent (at least thrice weekly)
resistance training for one year prior to the study] males
with an average age of 22.8 ± 4.67 yr, height of 179.5 ±
6.38 cm, and total body mass of 79.1 ± 16.13 kg com-
pleted the study. All participants passed a mandatory
medical screening. Participants with contraindications to
exercise as outlined by the American College of Sports
Medicine and/or who had consumed any nutritional sup-
plements (excluding multi-vitamins) such creatine mono-
hydrate, nitric oxide, hydroxy-beta-methylbutyrate
(HMB), various androstenedione derivatives, or pharma-
cologic agents such as anabolic steroids three months
prior to the study were not allowed to participate. All eli-
gible subjects signed a university-approved informed con-
sent document. Additionally, all experimental procedures
involved in this study conformed to the ethical consider-
ations of the Helsinki Code.
Testing sessions
The study included baseline testing at day 0 followed by a
follow-up testing session at day 29 in which blood and
muscle samples were obtained and where body composi-
tion and muscle performance tests were performed.
Strength assessment
Upper- and lower-body one repetition maximum (1-RM)
strength tests were performed using the free weight bench
press and angled leg press exercises (Nebula, Versailles,
OH), respectively. Initially, an estimated 50% (1-RM)
measured from the previous testing 1-RM test, was uti-
lized to complete 5 to 10 repetitions. After a two min rest
period, a load of 70% of estimated (1-RM) was utilized to
perform 3 to 5 repetitions. Weight was gradually increased
until a 1-RM was reached with each following lift, with a
two min rest period in between each successful lift. Test-
retest reliability of performing these strength assessments
on subjects within our laboratory has demonstrated low
mean coefficients of variation and high reliability for the
bench press (1.9%, intraclass r  = 0.94) and leg press
(0.7%, intraclass r = 0.91), respectively.
Body composition assessment
Total body mass (kg) was determined on a standard dual
beam balance scale (Detecto Bridgeview, IL). Percent
body fat, fat mass, and fat-free mass were determined
using DEXA (Hologic Discovery Series W, Waltham, MA).
Quality control calibration procedures were performed on
a spine phantom (Hologic X-CALIBER Model DPA/QDR-
1 anthropometric spine phantom) and a density step cal-
ibration phantom prior to each testing session. The DEXA
scans were segmented into regions (right & left arm, right
& left leg, and trunk). Each of these segments was ana-
lyzed for fat mass, lean mass, and bone mass.
Total body water volume was determined by bioelectric
impedance analysis (Xitron Technologies Inc., San Diego,
CA) using a low energy, high frequency current (500Journal of the International Society of Sports Nutrition 2009, 6:16 http://www.jissn.com/content/6/1/16
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micro-amps at a frequency of 50 kHz). Based on previous
studies in our laboratory, the accuracy of the DEXA for
body composition assessment is ± 2% as assessed by
direct comparison with hydrodensitometry and scale
weight. Test-retest reliability of performing assessments of
total body water on subjects within our laboratory has
demonstrated low mean coefficients of variation and high
reliability (2.4%, intraclass r = 0.91).
Venous blood sampling and percutaneous muscle biopsies
Venous blood samples were obtained from the antecu-
bital vein into a 10 ml collection tube using a standard
vacutainer apparatus. Blood samples were allowed to
stand at room temperature for 10 min and then centri-
fuged. The serum was removed and frozen at -80°C for
later analysis.
Percutaneous muscle biopsies (50–70 mg) were obtained
from the middle portion of the vastus lateralis muscle of
the dominant leg at the midpoint between the patella and
the greater trochanter of the femur at a depth between 1
and 2 cm. After sample removal, adipose tissue was
trimmed from the muscle specimens, immediately frozen
in liquid nitrogen, and stored at -80°C for later analysis.
Supplementation protocol and dietary monitoring
Participants were assigned to a 28-day supplementation
protocol, in double-blind placebo controlled manner.
Participants ingested either 27 g/day of placebo (malto-
dextrose) or 27 g/day of NO-Shotgun® (Vital Pharmaceu-
ticals, Inc., Davie, FL). NO-Shotgun contains a proprietary
blend of a number of compounds, but those assumed to
target muscle strength and mass are creatine monohy-
drate, beta-alanine, arginine, KIC, and leucine. For each
supplement, the dosage was ingested 30 min prior to each
exercise session. For days where no exercise occurs, the full
dosage of each supplement was ingested in the morning
upon waking. Participants completed supplementation
compliance questionnaires and returned empty bottles
during the post-study testing session.
For dietary analysis, participants were required to record
their dietary intake for four days prior to each of the two
testing sessions at day 0 and day 29 blood and muscle
samples were obtained. The participants' diets were not
standardized and subjects were asked not to change their
dietary habits during the course of the study. The four-day
dietary recalls will be evaluated with the Food Processor
IV Nutrition Software (ESHA, Salem OR) to determine the
average daily macronutrient consumption of fat, carbohy-
drate, and protein in the diet for the duration of the study.
Resistance-training protocol
Participants completed a periodized 28-day resistance-
training program split into two upper-extremity and two
lower-extremity exercise sessions each wk for 28 days. This
constituted a total of 16 exercise sessions, with eight
upper-body and eight lower-body exercise sessions. Prior
to each exercise session, participants performed a stand-
ardized series of stretching exercises. The participants then
performed an upper-extremity resistance-training pro-
gram consisting of nine exercises (bench press, lat pull,
shoulder press, seated rows, shoulder shrugs, chest flies,
biceps curl, triceps press down, and abdominal curls)
twice per week and a program consisting of seven lower-
extremity exercises (leg press, back extension, step ups, leg
curls, leg extension, heel raises, and abdominal crunches).
Participants performed three sets of 10 repetitions at 70 –
80% 1-RM. Rest periods were two min between exercises
and between sets. The resistance exercise sessions were not
supervised; however, it was required that each participant
completed detailed daily resistance-training logs.
Whole blood and serum clinical chemistry analyses
Whole blood was collected and immediately analyzed for
standard cell blood counts with percentage differentials
(hemoglobin, hematocrit, RBC, MCV, MCH, MCHC,
RDW, WBC counts, neutrophils, lymphocytes, mono-
cytes, eosinophils, basophils and leukocyte differentials)
using a Cell-Dyne 3500 (Abbott Diagnostics, Dallas, TX)
automated hematology analyzer. The instrument's flow
system was primed and the background counts checked
daily to ensure appropriate RBC and WBC linearity. The
coefficients of variation for the Cell-Dyne 3500 are
0.8747%, 0.8830%, 0.0296%, 0.7903%, and 0.8534% for
neutrophils, lymphocytes, monocytes, eosinophils, and
basophils, respectively.
Using a Dade Dimension RXL Analyzer (Dade Behring,
Newark, DE), serum samples were assayed for general
clinical chemistry markers (total cholesterol, high-density
lipoproteins, low-density lipoproteins, triglycerides, albu-
min, glucose, GGT, LDH, uric acid, BUN, creatinine,
BUN/creatinine ratio, calcium, creatine kinase, total pro-
tein, total bilirubin, ALP, ALT, and AST). This clinical
chemistry analyzer was calibrated daily using liquid assay
multiqual (BIO-RAD, Hercules, CA). For all assays men-
tioned above, the coefficients of variation are less than
5%.
Serum IGF-1 and HGF analyses
Serum samples were analyzed in duplicate for free/bioac-
tive IGF-1 (Diagnostic Systems Laboratories, Webster, TX)
and HGF (Biosource, Camarillo, CA) using an ELISA. For
IGF-1, this assay has a sensitivity of 0.06 ng/ml, and does
not cross-react with albumins or GH binding proteins. For
HGF, the sensitivity is 10 pg/ml. For both IGF-1 and HGF,
the subsequent absorbances, which were directly propor-
tional to the concentration of analyte in the sample, were
measured at a wavelength of 450 nm using a microplateJournal of the International Society of Sports Nutrition 2009, 6:16 http://www.jissn.com/content/6/1/16
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reader (Wallac Victor 1420, Perkin Elmer, Boston MA). A
set of standards of known concentrations for IGF-1 and
HGF were utilized to construct standard curves by plotting
the net absorbance values of the standards against their
respective protein concentrations. By applying a four part
parameter curve using MikroWin microplate data reduc-
tion software (Microtek Lab Systems, Germany), the free
IGF-1 and HGF concentrations in the serum samples were
calculated. The overall intra-assay percent coefficient of
variation was 4.9% and 3.3% for IGF-1 and HGF, respec-
tively.
Skeletal muscle phosphorylated c-met content and MRF 
ELISAs
Approximately 20 mg of each muscle sample was weighed
and subsequently homogenized using a commercial cell
extraction buffer (Biosource, Camarillo, CA) and a tissue
homogenizer. The cell extraction buffer was supple-
mented with 1 mM phenylmethanesulphonylfluoride
(PMSF) and a protease inhibitor cocktail (Sigma Chemi-
cal Company, St. Louis, MO) with broad specificity for the
inhibition of serine, cysteine, and metallo-proteases.
Muscle homogenate samples were analyzed for phospho-
rylated c-met (Tyr1230/Tyr1234/Tyr1235) using a phos-
phoELISA kit (Millipore, Billerica, MA). This sensitivity of
this particular assay is reported to be 0.78 U/ml. The
absorbances, which are directly proportional to the con-
centration of c-met in the samples, were measured at 450
nm with a microplate reader (Wallac Victor 1420, Perkin
Elmer, Boston MA). A set of standards of known concen-
trations for c-met were utilized to construct standard
curves by plotting the net absorbance values of the stand-
ards against their respective protein concentrations. By
applying a four part parameter curve using MikroWin
microplate data reduction software (Microtek Lab Sys-
tems, Germany), the c-met concentrations in the muscle
samples were appropriately calculated. The overall intra-
assay percent coefficient of variation was 6.89%
The muscle protein expression of the MRFs was assessed
through the use of ELISAs. Polyclonal antibodies specific
for Myo-D, myogenin, MRF-4, and myf5 (where their tar-
get specificities had been verified by Western blotting)
were purchased from Santa Cruz Biotech (Santa Cruz,
CA). Initially, the antibodies were diluted to 1 μg/ml in
coating buffer (Na2CO3, NaHCO3, and ddH2O, pH 9.6)
and allowed to incubate at room temperature overnight.
Following incubation, the plates were washed (1× phos-
phate buffered saline, Tween-20), blocked (10× phos-
phate buffered saline, bovine serum albumin, ddH2O),
washed, and then incubated with a secondary antibody
(IgG conjugated to HRP) diluted to 1 μg/ml in dilution
buffer (10× phosphate buffered saline, Tween-20, bovine
serum albumin, ddH2O). After washing, a stabilized TMB
chromogen was added and the plates were covered and
placed in the dark for the last 30-min prior to being
stopped with 0.2 M sulphuric acid. The subsequent
absorbances, which are directly proportional to the con-
centration of the MRFs in the samples, were measured at
a wavelength of 450 nm. There were no standards used in
these ELISAs, thus no standard curve was created. There-
fore, the absorbances relative to muscle weight were
assessed and compared as percent changes. The overall
intra-assay percent coefficients of variation were 7.12%,
6.47%, 8.03%, and 6.57% for Myo-D, myogenin, MRF-4,
and myf5, respectively.
Myofibrillar protein content
Total cellular RNA was extracted from biopsy samples
with a monophasic solution of phenol and guanidine iso-
thiocyanate contained within the TRI-reagent (Sigma
Chemical Co., St. Louis, MO), and then isolated with
100% isopropanol. The interphase was removed and total
(soluble + insoluble) muscle protein was then isolated
from the organic phase with 100% isopropanol and
washed with a 0.3 M guanidine HCl/95% ethanol solu-
tion. Myofibrillar (soluble) protein was further isolated
with repeated incubations in 0.1% SDS at 50°C and sep-
arated by centrifugation. Total and myofibrillar protein
content were determined spectrophotometrically based
on the Bradford method at a wavelength of 595 nm [33].
A standard curve was generated (R = 0.98, p = 0.001) using
bovine serum albumin (Bio-Rad, Hercules, CA), and total
and myofibrillar protein content was expressed relative to
muscle wet-weight [34].
Total DNA content
Total DNA was isolated from the remaining interphase
from the total RNA isolation procedure using 100% etha-
nol, washed with a 0.1 M sodium citrate/10% ethanol
solution, and resuspended in 75% ethanol. The DNA was
then solubilized in 8 mM NaOH. The total DNA concen-
tration was determined spectrophotometerically (Helio γ,
Thermo Electron, Milford, MA) by optical density (OD) at
260 nm using an OD260 equivalent to 50 μg/μl [35]. At a
wavelength of 260 nm, the average extinction coefficient
for DNA is 0.024 μg/ml; therefore, an OD of 1.0 corre-
sponds to a DNA concentration of 50 μg/ml. The final
DNA concentration was expressed relative to muscle wet-
weight.
Reported side effects from supplements
On day 29, participants reported by questionnaire
whether they tolerated the supplement, supplementation
protocol, as well as report any medical problems and/or
symptoms they may have encountered throughout the
study.
Statistical analysis
With the exception of the MRFs, all data were analyzed
with separate 2 (group) × 2 (time) univariate ANOVAJournal of the International Society of Sports Nutrition 2009, 6:16 http://www.jissn.com/content/6/1/16
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with repeated measures on the time factor with SPSS for
Windows Version 16.0 software (SPSS inc., Chicago, IL).
Significant differences among groups were identified by a
Tukey HSD post-hoc test. For the MRFs, the percent
changes from Day 0 to Day 29 were analyzed with sepa-
rate independent group t-tests (p < 0.05). A probability
level of ≤ 0.05 was adopted throughout.
Results
Subject demographics
Twenty participants began the study; however, two
dropped out due to reasons unrelated to the study. As a
result, 18 participants completed the study. The PL group
(n = 9) had an average (± SD) age of 22.77 ± 4.91 yr,
height of 179.49 ± 8.32 cm, and total body mass of 79.31
± 17.35 kg. The NO group (n = 9) had age of 22.88 ± 4.70
yr, height of 179.56 ± 4.33 cm, and total body mass of
78.89 ± 15.87 kg. No significant differences were observed
between groups for age (p = 0.46), height (p = 0.32), or
total body mass (p = 0.27).
Dietary analysis, supplement compliance, and reported 
side effects
The diet logs were used to analyze the average caloric and
macronutrient consumption relative to total body mass
(Table 1). No significant differences existed between
groups for total calories (p = 0.12), protein (p = 0.19), car-
bohydrate (p = 0.18), or fat calories (p = 0.13); however,
significant main effects for Time existed for both groups
for total calories (p < 0.001), protein (p < 0.001), carbo-
hydrate (p < 0.001), and fat (p < 0.001).
All participants appeared to have exhibited 100% compli-
ance with the supplement protocol, and were able to com-
plete the required dosing regimen and testing procedures.
Over the course of the 28 days, four participants in PL and
four in NO reported side effects. For PL, two participants
reported feelings of nausea, one reported a rapid heart
rate, and one reported shortness of breath. For NO, two
participants reported dizziness, two reported feelings of
nausea, two reported headache, two reported a rapid heart
rate, one reported shortness of breath, and two reported
nervousness.
Body composition
For total body mass, both groups increased with training
(p = 0.001) with a strong trend for NO to be significantly
greater than PL (p = 0.062). No training (p = 0.77) or sup-
plement related (p = 0.35) changes were seen with total
body water. In addition, no training (p = 0.62) or supple-
ment related (p = 0.23) changes were seen with fat mass;
however fat-free mass did increase with training (p <
0.001) and the increases seen with NO were significantly
greater than PL (p < 0.001) (Table 2).
Muscle strength
Bench press (p = 0.005) and leg press (p < 0.001) strength
were both increased with training. For bench press
strength, NO was significantly greater than PL (p = 0.003.
Serum markers of satellite cell activation (IGF-1 and HGF)
Serum IGF-1 was significantly increased with training (p =
0.046); however, NO and PL did not differ relative to IGF-
1 (p = 0.86). Serum HGF was also significantly increased
with training for NO (p = 0.006), with this increase being
significantly greater than PL (p = 0.02) (Table 3).
Skeletal muscle markers of satellite cell activation
Muscle phosphorylated c-met was increased with training
(p = 0.019) with a strong trend for NO to be significantly
greater than PL (p = 0.067). For total DNA, both groups
increased with training (p = 0.008) and the increases
observed in NO were significantly greater than PL (p =
0.042). All of the myogenic regulatory factors were
increased with training; however, NO was shown to be
significantly greater than PL for Myo-D (p = 0.008) and
MRF-4 (p = 0.022 (Figure 1).
Myofibrillar protein, total DNA content, and DNA/protein
For myofibrillar protein, both groups increased with train-
ing (p < 0.001) and the increases observed in NO were sig-
nificantly greater than PL (p = 0.014) (Table 3). In
Table 1: Dietary Caloric and Macronutrient Intake
Group PL Day 0 PL Day 29 NO Day 0 NO Day 29 Group Time G × T
Total Calories (kcal/kg) 33.92 (8.51) 35.67 (8.40) 27.88 (7.47) 28.80 (6.94) 0.13 0.001 0.12
Protein (kcal/kg) 1.39 (0.50) 1.69 (0.47) 1.29 (0.30) 1.56 (0.23) 0.14 0.001 0.19
Fat (kcal/kg) 1.48 (0.47) 1.26 (0.43) 1.09 (0.34) 0.99 (0.29) 0.17 0.001 0.18
Carbohydrate (kcal/kg) 4.81 (1.98) 4.88 (1.43) 3.31 (0.97) 3.85 (1.06) 0.19 0.001 0.13
Data are presented as means and standard deviations of daily caloric values expressed relative to total body mass (kcal/kg). No significant 
interactions existed for total calories, protein, carbohydrate, or fat calories (p > 0.05). However, significant main effects for time existed for both 
groups for all four variables (p < 0.001).Journal of the International Society of Sports Nutrition 2009, 6:16 http://www.jissn.com/content/6/1/16
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addition, for total DNA content, both groups increased
with training (p < 0.011) and the increases observed in
NO were significantly greater than PL (p = 0.041) (Table
3). For DNA/protein, a strong trend was observed but
there were no significant changes with training (p =
0.061) and no significant differences between groups (p =
0.14) (Table 3).
Serum and whole blood clinical chemistry markers
The whole blood and serum markers assessed remained
within normal clinical ranges throughout the duration of
the study. As a result, no significant differences between
groups (p > 0.05) or main effects for Time (p > 0.05) were
observed for any of the serum (Table 4) and whole blood
(Table 5) clinical chemistry markers.
Discussion
The results of the present study support our hypothesis,
indicating that NO-Shotgun®  supplementation in con-
junction with a 28 days of heavy resistance training, is
effective at increasing fat-free mass, muscle strength and
mass, myofibrillar protein content, and markers of satel-
lite cell activation, while having no effect on whole blood
and serum clinical safety markers in untrained males. Our
results agree with previously reported studies that resist-
ance training, when performed in conjunction with creat-
ine [24,25], whey protein and leucine [36], and HMB
[37,38] is effective at improving body composition, mus-
cle strength and mass and markers of satellite cell activa-
tion.
We observed both NO and PL to significantly increase
total body mass (P = 0.001). Additionally, fat-free mass
was increased in both groups, and the 4.75% increase in
NO was significantly greater than the 1.69% increase in
PL. These findings are similar to results observed after 12
wk of heavy resistance training and creatine supplementa-
tion, where fat-free mass was increased 9.44% in the crea-
Table 2: Means, standard deviations, and percent changes for body composition and muscle strength variables in the study.
Variable PL Day 0 PL Day 29 % Change NO Day 0 NO Day 29 % Change Time Group × Time
Body Weight (kg) 79.31 80.4 1.37 78.57 80.48 2.59 p = 0.001 p = 0.062
17.35 17.57 0.91 15.84 15.54 1.65
Fat Mass (kg) 14.93 15.07 4.85 15.89 15.52 -1.21 p = 0.62 p = 0.23
11.84 11.16 8.17 10.92 10.13 6.15
Fat-Free Mass (kg) 54.89 55.84 1.69 53.95 56.46 4.75 p = 0.001 p = 0.001
6.43 6.79 1.62 6.41 6.23 1.49
Total Body Water (L) 42.82 43.34 1.17 40.61 41.92 3.36 p = 0.77 p = 0.35
5.73 5.96 2.18 4.55 4.32 3.06
Bench Press (kg/kg) 0.908 0.918 0.73 0.779 0.84 8.82 p = 0.005 p = 0.003
0.223 0.239 6.92 0.215 0.198 5.34
Leg Press (kg/kg) 3.77 4.21 11.99 3.56 4.22 18.4 p = 0.001 p = 0.10
0.69 0.73 8.36 0.93 1.14 5.74Journal of the International Society of Sports Nutrition 2009, 6:16 http://www.jissn.com/content/6/1/16
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tine group and 1.84% in the carbohydrate placebo group
[24]. In addition, 10 wk of heavy resistance training and
whey protein and amino acid supplementation resulted
in increases in fat-free mass of 5.62% compared to
increases of 2.70% for carbohydrate placebo [34].
Relative to muscle strength, we observed NO to increase in
bench press and leg press strength by 8.82% and 18.40%,
respectively, compared to the respective increases in
bench press and leg press strength of 0.74% and 10.30%
for PL. However, only bench press was significantly
greater for NO compared to PL (p = 0.003). Our observed
increases in muscle strength are supported by previous
studies which demonstrated heavy resistance training,
when combined with creatine [24,27], protein and amino
acids (34), and whey protein and leucine [24] to improve
strength levels when compared to placebo. However, it
should be noted that NO-Shotgun® contains beta-alanine,
which has been shown to possibly potentiate the effects of
creatine. A recent study has shown that 10 wk of resistance
training combined with creatine and beta-alanine pro-
duced superior gains in strength and fat-free mass com-
pared to creatine or placebo [39].
In the present study, we also showed that after 28 days of
heavy resistance training and supplementation NO under-
went increases in myofibrillar protein of 70.39% that
were significantly greater than the 26.34% increase in PL
(p < 0.001), and that the increases for NO were signifi-
cantly different than PL (p = 0.014). This is a similar pat-
tern of response from longer-term studies where creatine
supplementation, in conjunction with 12 wk of resistance
training, resulted in a 57.92% increase in myofibrillar
protein content when compared to a maltodextrose pla-
cebo group, which only increased 11.62% [24]. In addi-
tion, 10 wk of heavy resistance training combined with a
Table 3: Serum and selected muscle variables for the Placebo and NO-Shotgun Groups at Days 0 and 29.
PL Day 0 PL Day 29 % Change NO Day 0 NO Day 29 % Change Time Group × Time
Serum IGF-1 (ng/ml) 238.61 246.98 8.58 239.04 259.81 9.34 p = 0.046 p = 0.86
108.68 122.63 37.3 87.57 97.32 20.01
Serum HGF (pg/ml) 238.54 199.54 -8.71 251.21 344.34 47.42 p = 0.006 p = 0.02
89.72 75.02 34.06 69.87 232.14 62.49
Muscle c-met (ng/mg) 13.34 14.06 8.55 7.82 12.9 118.55 p = 0.019 p = 0.067
8.19 9.76 48.34 8.14 9.64 102.49
Myofibrillar Protein (μg/mg) 86.18 108.41 26.34 81.47 135.83 70.39 p = 0.001 p = 0.014
10.27 26.92 15.06 12.14 18.15 37.66
Total DNA (ug/mg) 27.79 29.59 4.67 27.89 52.37 88.75 p = 0.011 p = 0.041
5.96 11.35 26.41 3.29 7.74 26.81
DNA/Protein 0.32 0.28 -8.77 0.34 0.39 14.22 p = 0.061 p = 0.14
0.06 0.12 42.24 0.04 0.09 23.76
Data are presented as means, standard deviations, and percent changes.Journal of the International Society of Sports Nutrition 2009, 6:16 http://www.jissn.com/content/6/1/16
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protein and amino acid supplement resulted in a 25.03%
increase in myofibrillar protein compared to 10.54% for a
carbohydrate placebo [34].
We have demonstrated 28 days of heavy resistance train-
ing to increase serum IGF-1 by 9.34% and 8.58%, respec-
tively for NO and PL; however, there was no difference
between groups. Treating C2C12 myoblasts with creatine
has been shown to increase the expression of the IGF-1
peptide [40]. A positive relationship has been reported
between IGF-1 peptide and total DNA content in muscle
during resistance exercise due to satellite cell proliferation
stimulated by the locally produced IGF-1 [7]. However,
while the IGF-I peptide expressed in skeletal musclein-
creases muscular protein synthesis and stimulates differ-
entiation of proliferating satellite cells [14,41], it is
unclear whether increases in hepatically-derived circulat-
ing IGF-1 has any direct effect on muscle hypertrophy. We
have previously shown that 10 wk of heavy resistance
training combined with a daily supplement containing
whey/casein protein and free amino acids increased circu-
lating IGF-1 levels, while also increasing muscle strength
and mass [34]. Additionally, 16 wk of resistance training
has been shown to increase circulating IGF-1 levels [42].
However, 12 wk of heavy resistance training has been
shown to increase muscle strength and mass without any
corresponding increases in circulating IGF-1 [43].
Increases in muscle hypertrophy independent of increases
in circulating IGF-1 can possibly be explained by a recent
study using a liver IGF-1 deficient mouse model, which
involves a reduction in serum IGF-1 of approximately
80% [44]. After 16 wk of resistance training, the IGF-1-
deficient mice and control mice exhibited equivalent
gains in muscle strength, suggesting that performance and
recovery in response to resistance training is normal even
when there is a severe deficiency in circulating IGF-1.
HGF is a growth factor bound to an extracellular matrix in
skeletal muscle [45] that is capable of activating quiescent
satellite cells [46]. Serum HGF levels have been shown to
increase 24 hr following a single bout of eccentric exercise
[47]. In cultured satellite cells, mechanical stretch has
been shown to induce the activity of nitric oxide synthase
and increase nitric oxide production, which was associ-
ated with increases in HGF [48]. In the present study, for
serum HGF we observed PL to decrease 8.71% with train-
ing, whereas NO increased 47.42%. Based on the fact that
NO-Shotgun® contains arginine, an alleged mediator of
nitric oxide synthesis, our results may be partially
explained on the premise that nitric oxide mediates the
release of HGF, and that nitric oxide synthase activity is
increased with satellite cell activation.
Skeletal muscle markers of satellite cell activation exam-
ined in this study were phospoyrlated c-met (the proto-
oncogene receptor for HGF), total DNA, and the MRFs
(MyoD, Myf5, MRF-4, and myogenin). While circulating
levels of HGF were increased for NO, skeletal muscle
phosphorylated c-met was also increased for NO from
resistance training by 118.55% (p = 0.019), with a strong
trend for NO to be significantly greater than PL (p =
0.067). Increases in the phosphorylation of the HGF
receptor, c-met, may be indicative of a possible increase in
satellite cell activation. Since HGF levels increased signifi-
cantly for NO, an increase in the c-met receptor would
likely allow for increased binding of HGF.
Resistance training can increase the number of satellite
cells and increase myonuclei in the myofiber [11,12].
However, it has been shown that 16 wk of heavy resist-
ance training combined with creatine supplementation
augments satellite cell activation, as evidenced by
increases in skeletal muscle mean fiber and area myonu-
clear number to a much greater extent to whey protein or
resistance training alone [28]. Furthermore, the creatine
group was shown to have the greatest increase in maximal
isometric quadriceps contraction strength. Relative to
results for the whey protein group, it was shown to
undergo greater increases in skeletal muscle mean fiber
area and myonuclear number and isokinetic quadriceps
strength when compared to the control group.
In the present study, we did not directly assess satellite cell
or myonuclear number. Rather, we assessed markers that
are considered to be valid indicators of increased satellite
Data presented as means and standard deviations and  expressed as a percent change in absorbance units from Day  0 to Day 29 Figure 1
Data presented as means and standard deviations 
and expressed as a percent change in absorbance 
units from Day 0 to Day 29. All of the MRFs were signifi-
cantly increased with resistance training in both groups (p < 
0.05); however, NO was shown to be significantly greater 
than placebo for Myo-D (p = 0.008) and MRF-4 (p = 0.022), 
with weak trends for NO to be significantly greater than PL 
for myf5 (p = 0.091) and myogenin (p = 0.11). * indicates a 
significant increase with resistance training. † indicates NO 
to be significantly greater than PL.Journal of the International Society of Sports Nutrition 2009, 6:16 http://www.jissn.com/content/6/1/16
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cell activation. In so doing, both groups underwent
increases in all MRFs with heavy training. However, Myo-
D and MRF-4 showed significantly greater increases in NO
than PL. For NO, Myo-D increased by 70.91%, MRF-4
increased by 56.24%, myf5 increased by 54.38%, and
myogenin increased by 71.17%, while PL only increased
Myo-D increased by 11.53%, MRF-4 increased by 11.24%,
myf5 increased by 19.45%%, and myogenin increased by
28.15%. This is a noteworthy result, as MyoD and Myf5
are believed to be involved in satellite proliferation, and
myogenin and MRF-4 are involved in satellite cell differ-
entiation [17]. Therefore, our results suggest that NO may
have been undergoing a greater amount of satellite cell
proliferation and differentiation, as indicated by elevated
levels of MyoD and MRF-4, respectively.
We have demonstrated in the present study that total
DNA content for NO was increased 88.75%, whereas PL
was only increased 4.67% with training (p = 0.011), and
the increases observed in NO were significantly greater
than PL (p = 0.041). During muscle hypertrophy, myonu-
clei increase sequentially [49] as satellite cells proliferate,
fuse with muscle fibers and donate their nuclei, and
increase myonuclear number [50]. Consequently,
increases in myonuclear number and sarcoplasmic vol-
ume are proportional and the myocyte myonuclear
domain remains constant, thereby resulting in no appre-
ciable change in DNA/protein and subsequent mainte-
nance in the myonuclear domain. Conversely, because an
increase in myonuclear number expands the quantity of
DNA available for gene expression and subsequent pro-
Table 4: Serum Clinical Chemistry Markers for the Placebo and NO-Shotgun Groups at Days 0 and 29.
Variable PL Day 0 PL Day 29 NO Day 0 NO Day 29
Triglycerides (mg/dl) 80.63 (37.68) 75.38 (21.67) 108.38 (63.21) 92.25 (46.02)
Cholesterol (mg/dl) 152.25 (23.30) 158.23 (24.27) 179.38 (28.59) 176.63 (25.49)
HDL (mg/dl) 48.13 (8.64) 52.75 (8.82) 53.0 (6.57) 51.88 (8.17)
LDL (mg/dl) 89.38 (18.04) 91.13 (18.58) 106.38 (24.09) 106.5 (21.15)
GTT (U/L) 25.5 (10.07) 25.5 (10.28) 38.0 (36.07) 38.75 (33.70)
LDH (U/L) 109.13 (13.90) 126.0 (41.04) 106.75 (16.56) 112.63 (19.10)
Uric Acid (mg/dL) 5.8 (1.12) 5.5 (1.01) 5.56 (1.02) 5.69 (0.61)
Glucose (mg/dL) 88.38 (6.14) 89.25 (4.59) 90.88 (5.84) 89.13 (5.44)
BUN (mg/dL) 11.88 (3.14) 11.13 (2.30) 14.0 (3.02) 13.13 (3.87)
Creatinine (mg/dL) 0.9 (0.05) 1.04 (0.14) 1.03 (0.10) 1.04 (0.05)
BUN/Creatinine 13.24 (3.61) 10.75 (1.78) 13.75 (2.97) 12.54 (3.31)
Calcium (mg/dL) 8.91 (0.18) 9.03 (0.17) 9.14 (0.20) 9.01 (0.21)
Total Protein (g/dl) 7.31 (0.49) 7.46 (0.37) 7.66 (0.29) 7.59 (0.30)
Total Bilirubin (mg/dl) 0.6 (0.24) 0.53 (0.20) 0.56 (0.36) 0.54 (0.27)
ALP (U/L) 74.88 (25.49) 87.88 (32.30) 61.38 (19.09) 60.88 (18.43)
AST (U/L) 25.88 (20.64) 18.75 (7.19) 15.88 (7.38) 20.25 (14.65)
ALT (U/L) 32.25 (10.70) 29.5 (3.89) 25.88 (3.48) 31.0 (5.76)
CK (U/L) 144.63 (124.81) 138.88 (81.06) 88.88 (47.08) 83.0 (38.15)
Data are presented as means and standard deviations. No significant differences were observed with resistance training or between groups 
throughout the 28-day study for serum clinical chemistry variables (p > 0.05).Journal of the International Society of Sports Nutrition 2009, 6:16 http://www.jissn.com/content/6/1/16
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tein synthesis, the additional myonuclei will facilitate
skeletal muscle hypertrophy, thereby resulting in a
decrease in DNA/protein as more muscle protein is syn-
thesized from fewer myocytes/DNA [51]. Nuclei within
mature muscle fibers are mitotically inactive [52]; there-
fore, an increase in skeletal muscle DNA content is indic-
ative of myogenically-induced satellite cell activation.
We observed the increases in myofibrillar protein and
total DNA content to occur in both groups; however,
while DNA/protein was decreased in PL, it was main-
tained in NO. Both groups also underwent increase
increases in the MRFs and phosphorylated c-met, but the
increases were greater for NO. This scenario is conceivably
attributed to increases in satellite cell activation due to the
premise that initial muscle fiber hypertrophy can expand
the myonuclear domain as existing myonuclei increase
their protein synthesis to support moderate increases in
sarcoplasmic volume [12]. However, once a certain limit
in the myonuclear domain is reached, further myofiber
hypertrophy may only occur as a result of satellite cell acti-
vation and the subsequent addition of new myonuclei
[42]. Based on our results for the markers of myogenesis
and the maintenance of the myonuclear domain, the
present data suggest that the muscle hypetrophy occurring
in response to 28 days of heavy resistance exercise com-
bined with NO-Shotgun® supplementation appears to be
more effective at promoting the myogenic activation of
satellite cells than resistance exercise combined with a car-
bohydrate placebo. IGF-I activates phosphatidylinositol-3
kinase (PI3K) resulting in downstream phosphorylation
of Akt [30,53]. Creatine supplementation has also been
shown to enhance the differentiation of myogenic C2C12
cells by activating the p38 MAPK pathway, as the activa-
tion of p38 and the transcription factor, myocyte
enhancer factor 2 (MEF-2) were increased [29]. The p38
MAPK pathway is an important signaling pathway respon-
sible for up-regulating the expression of various sarcom-
eric genes in response to mechanical overload. The Akt/
mTOR pathway is an important pathway involved in up-
regulating translational activity en route to increases in
muscle protein synthesis. The Akt/mTOR pathway was
activated in C2C12 myoblasts treated with creatine, as Akt,
mTOR, and p70S6 kinase activity were elevated [29]. The
Akt/mTOR pathway can also be activated by leucine [30].
Supplemental leucine leads to increased levels of α-ketoi-
socaproate (KIC) [31], which inhibits the activity of the
branched-chain keto-acid dehydrogenase (BCKDH) com-
plex, thereby blunting BCAA oxidation [32] and muscle
proteolysis [54] during heavy resistance exercise. It has
been shown that 14 days of KIC and beta-hydroxy-beta-
Table 5: Whole Blood Clinical Chemistry Markers for the Placebo and NO-Shotgun Groups at Days 0 and 29.
Variable PL Day 0 PL Day 29 NO Day 0 NO Day 29
WBC (K/μl) 6.10 (1.28) 5.81 (1.35) 5.09 (1.25) 5.37 (2.06)
RBC (M/μL) 5.09 (0.29) 5.27 (0.42) 4.74 (0.26) 4.68 (0.23)
Hemoglobin (g/gl) 15.35 (1.04) 16.08 (1.36) 14.60 (0.68) 14.46 (0.53)
Hematocrit (%) 46.36 (1.92) 48.17 (3.29) 43.41 (1.70) 42.91(1.26)
MCV (fl) 91.11 (1.90) 91.46 (1.81) 91.67 (3.00) 91.90 (4.39)
MCH (pg) 30.13 (1.00) 30.50 (0.81) 30.80 (1.29) 30.91 (1.56)
MCHC (g/dl) 33.10 (1.15) 33.37 (1.03) 33.61 (0.59) 33.62 (0.29)
Lymphocytes (K/μl) 2.07 (0.26) 1.86 (0.43) 1.89 (0.44) 1.54 (0.34)
Monocytes (K/μl) 0.46 (0.15) 0.45 (0.21) 0.27 (0.21) 0.48 (0.24)
Neutrophils (K/μl) 3.34 (1.11) 3.19 (1.15) 2.67 (0.90) 3.02 (2.10)
Eosinophils (K/μl) 0.22 (0.18) 0.23 (0.17) 0.15 (0.11) 0.24 (0.14)
Basophils (K/μl) 0.06 (0.05) 0.06 (0.02) 0.07 (0.04) 0.07 (0.04)
Data are presented as means and standard deviations. No significant differences were observed with resistance training or between groups 
throughout the 28-day study for whole blood clinical chemistry variables (p > 0.05).Journal of the International Society of Sports Nutrition 2009, 6:16 http://www.jissn.com/content/6/1/16
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methylbutyrate (HMB) supplementation reduced signs
and symptoms of exercise-induced muscle damage in
untrained males following a single bout of eccentrically-
biased resistance exercise [55]. Furthermore, BCAA
ingested prior to 60 min of cycling exercise at 50% of max-
imal work capacity has been shown to attenuate exercise-
induced skeletal muscle proteolysis [56].
In regard to clinical safety measures, all of the whole
blood and serum markers assessed remained within nor-
mal clinical ranges throughout the duration of the study.
As a result, we observed no significant differences between
PL and NO, indicating NO-Shotgun® to have no deleteri-
ous effects with regard to the whole blood and serum var-
iables we assessed. The NO-Shotgun®  supplement
contains a number of different compounds with many of
these having little to no clinical safety data available.
However, there are safety data available for creatine. Cre-
atine is well-tolerated in most individuals in short-term
studies [57]. Nevertheless, idiosyncratic effects may occur
when large amounts of an exogenous substance contain-
ing an amino group are consumed, with the consequent
increased load on the liver and kidneys [58]. Therefore,
concerns have been raised regarding the long-term safety
of creatine supplementation. To date, however, studies
consisting of durations of nine wk to five yr have not
found clinically significant deviations from normal values
in renal, hepatic, and cardiac safety markers in healthy
individuals [58].
NO-Shotgun® is a nutritional supplement that contains a
synergistic blend of compounds, such as creatine, leucine,
KIC, and arginine which have been shown in previous
studies to be effective at increasing muscle strength and
mass, myofibrillar protein content, muscle protein syn-
thesis, and satellite cell activation. Based on the results
presented herein, it is difficult to conclude whether any
one compound or the additive and/or synergistic effects of
various compounds contained in NO-Shotgun®  were
responsible for eliciting the effects we observed to occur.
Therefore, we conclude that 28 days resistance training,
when supplemented with NO-Shotgun®, has no negative
effects on the clinical safety markers assessed, while effec-
tively increasing muscle strength and mass, myofibrillar
protein content, and stimulating increases in myogenic
markers indicative of satellite cell activation.
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